Evommune, Inc. (EVMN)
| Market Cap | 908.74M |
| Revenue (ttm) | 13.00M |
| Net Income (ttm) | -68.87M |
| Shares Out | 36.02M |
| EPS (ttm) | -11.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,977 |
| Open | 25.28 |
| Previous Close | 25.00 |
| Day's Range | 24.83 - 25.64 |
| 52-Week Range | 13.89 - 33.20 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 43.88 (+73.92%) |
| Earnings Date | Jun 11, 2026 |
About EVMN
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California. [Read more]
Financial Performance
In 2025, Evommune's revenue was $13.00 million, an increase of 85.71% compared to the previous year's $7.00 million. Losses were -$68.87 million, 0.82% more than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for EVMN stock is "Strong Buy." The 12-month stock price target is $43.88, which is an increase of 73.92% from the latest price.
News
Evommune Transcript: Status update
A new phase IIb trial will evaluate EVO756, an oral MRGPRX2 antagonist, for migraine prevention, aiming to address unmet needs beyond current CGRP therapies. The program leverages strong mechanistic rationale and seeks to disrupt neuroinflammatory cycles in migraine, with top-line data expected in 2027.
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Announces $125 Million Private Placement
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
Evommune, Inc. (NASDAQ: EVMN) shares are trading lower on Thursday on profit-taking after the stock soared around 70% on Wednesday.
Evommune's Stock Surges On Strong Results For New Eczema Drug
The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg on day 1 and day 28 (n=48 active, n=22 placebo) over 12 weeks.
Evommune Transcript: Study result
EVO301 met its primary and secondary endpoints in a phase 2A trial for moderate to severe atopic dermatitis, showing rapid, durable, and statistically significant efficacy with a clean safety profile after just two doses. The drug demonstrated broad anti-inflammatory activity and is advancing to phase 2B with a subcutaneous formulation.
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
PALO ALTO, Calif.--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory ...
Evommune Announces Pricing of its Initial Public Offering
PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory dis...
Evommune Announces Commencement of Initial Public Offering
PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory di...
Evommune files for IPO to advance immune drug work
The company has a pair of drugs in mid-stage testing for urticarias and atopic dermatitis.
Evommune IPO Registration Document (S-1)
Evommune has filed to go public with an IPO on the New York Stock Exchange (NYSE)
Chronic inflammatory disease biotech Evommune files for a $100 million IPO
Evommune, a Phase 2 biotech developing therapies for chronic inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
Evommune Transcript: Study Result
EVO756 demonstrated robust efficacy and safety in a phase II trial for chronic inducible urticaria, with 30% of patients achieving complete response and 93% showing improvement in key measures at four weeks. Results support further development in CSU and atopic dermatitis.